Amgen Carmot Collaboration Kras G12c Amg 510

The Amgen–Carmot Collaboration, KRAS G12C, and AMG 510: What the Cancer World Was Watching

If you've been following oncology news over the last several years, you've probably seen the name KRAS G12C come up a lot. On top of that, it's one of those mutations that was considered "undruggable" for decades — a stubborn biological problem that frustrated researchers and left patients with limited options. Then came a wave of companies and collaborations aiming to crack it open, and the Amgen–Carmot partnership around KRAS G12C and AMG 510 sits right at the center of that story.

So what's actually going on here? And why does this collaboration matter beyond just another deal announcement in the biotech world?

What Is the Amgen–Carmot Collaboration Around KRAS G12C and AMG 510?

Let's break this down piece by piece, because the details get tangled fast.

What KRAS G12C Actually Is

KRAS is a gene that produces a protein involved in cell signaling — basically, it helps tell cells when to grow and divide. When KRAS mutates, it can get stuck in the "on" position, driving uncontrolled cell growth. G12C is a specific mutation where a glycine amino acid at position 12 gets replaced by cysteine. This particular mutation is found in a meaningful share of non-small cell lung cancer (NSCLC) cases, and it also shows up in colorectal cancer and pancreatic cancer, among others.

For a long time, KRAS was the poster child for "undruggable" targets in oncology. The protein's structure seemed to resist the kinds of small molecules that drug designers typically use. The G12C mutation, however, turned out to have a slightly different shape — a pocket that could, in theory, be targeted. That changed everything.

Who Carmot Therapeutics Is

Carmot Therapeutics was a San Francisco–based biotech company focused on developing small-molecule drugs, particularly in oncology. They built a platform for identifying and optimizing molecules that could bind to specific targets, and KRAS G12C was one of the areas they pursued.

What Amgen Brought to the Table

Amgen, the large California-based biopharma company, has a long history in oncology and a deep interest in KRAS. AMG 510 was Amgen's own KRAS G12C inhibitor — a molecule designed to latch onto the mutated KRAS protein and shut down its cancer-driving signals. AMG 510 entered clinical trials and generated significant interest as one of the early KRAS G12C-targeted therapies.

The Collaboration Itself

The Amgen–Carmot collaboration involved Amgen licensing or working with Carmot's KRAS G12C program. The general idea was to combine Carmot's expertise and early-stage assets with Amgen's development infrastructure and clinical experience to advance KRAS G12C-targeting therapies. The exact structure of the deal — whether it was a licensing agreement, a broader collaboration, or something else — involved financial terms that have been reported in general terms but where specific figures are best confirmed through official SEC filings and press releases rather than secondary sources.

AMG 510 itself was a key part of this landscape. It was Amgen's investigational KRAS G12C inhibitor that moved through early-phase clinical trials, generating data on safety, dosing, and initial signs of anti-tumor activity in patients whose cancers carried the G12C mutation.

Why This Collaboration and AMG 510 Matter

A Long-Sought Target Finally Has Drugs

For decades, KRAS was the mutation everyone wanted to drug but couldn't. Consider this: when AMG 510 and similar KRAS G12C inhibitors started showing activity in clinical settings, it was a landmark moment. The Amgen–Carmot collaboration was part of the broader push to bring multiple KRAS G12C options to patients, which matters because competition and diversity in approaches can improve outcomes.

Filling a Gap in Hard-to-Treat Cancers

Patients with KRAS G12C mutations in NSCLC, colorectal cancer, and other solid tumors historically had few targeted options. Chemotherapy and immunotherapy helped some, but having a drug designed specifically for the mutation itself was a different kind of advance. The collaboration between Amgen and Carmot was aimed at expanding the toolkit for these patients.

If you found this helpful, you might also enjoy can sugar be dissolved in water or what is pencil lead made of.

A Proof of Concept for "Undruggable" Targets

The success of KRAS G12C inhibitors — including AMG 510 — has had ripple effects beyond just one mutation. It gave the broader drug development community confidence that other previously "undruggable" targets might be tractable too. That's a big deal for the entire field.

How the Science Behind KRAS G12C Targeting Works

The Cysteine Pocket

The G12C mutation creates a unique structural feature on the KRAS protein. That said, the substitution of cysteine for glycine at position 12 leaves a nearby pocket that didn't exist before — or at least wasn't accessible in the same way. Small molecules can be designed to fit into this pocket and bind to the mutant protein, locking it in an inactive state.

Covalent Binding Mechanism

Many KRAS G12C inhibitors, including AMG 510, use a covalent binding approach. This means the drug forms a permanent

Covalent Binding and Its Consequences

The covalent strategy hinges on the unique chemistry of the G12C cysteine. After the small molecule occupies the pocket, a reactive electrophilic warhead forms a reversible or irreversible bond with the thiol side chain of Cys12. Plus, this attachment locks KRAS in an inactive conformation, preventing downstream signaling through the MAPK pathway. Because the bond is covalent, the inhibitor’s residence time on the target is extended compared with reversible binders, which can translate into sustained pathway suppression even after plasma concentrations fall.

toxicity. To mitigate these risks, researchers have focused on optimizing the electrophilic warhead to balance potency with selectivity, ensuring that the molecule reacts preferentially with the mutant cysteine while sparing wild-type proteins.

Overcoming Resistance Mechanisms

Despite initial success, resistance to KRAS G12C inhibitors inevitably emerges. But tumor cells may develop secondary mutations that alter the binding pocket, upregulate alternative signaling pathways, or increase drug efflux. To address this, combination therapies are being explored, pairing KRAS G12C inhibitors with agents that block compensatory pathways such as SHP2, EGFR, or MEK. These strategies aim to delay or prevent resistance, prolonging clinical benefit for patients.

Expanding Beyond NSCLC

While non-small cell lung cancer (NSCLC) was the first approved indication, KRAS G12C inhibitors are now being evaluated in colorectal cancer, pancreatic cancer, and other malignancies. Each tumor type presents unique challenges, such as differential pathway dependencies and tumor microenvironment interactions. Ongoing trials continue to refine patient selection criteria and identify biomarkers that predict response.

Looking Ahead: Next-Generation Inhibitors and Broader Applications

The journey from concept to clinic for KRAS G12C inhibitors represents a turning point in precision oncology. Building on this success, researchers are now developing next-generation compounds that may overcome existing resistance mechanisms or target other KRAS mutations, such as G12D or G13D. Additionally, efforts are underway to explore combination regimens that enhance efficacy while minimizing toxicity.

Conclusion

The development of KRAS G12C inhibitors like AMG 510 marks a transformative milestone in cancer treatment. By directly targeting a mutation once considered undruggable, these therapies have offered new hope to patients with limited options. As research continues to evolve, the lessons learned from KRAS G12C inhibition will likely inform the development of treatments for other challenging oncogenic drivers, reinforcing the power of innovative drug design in the fight against cancer.